Some parts of a personalised treatment are reused for every recipient, such as the manufacturing process. Others are chosen for one person, such as the sequence of the vaccine or the person's own cells. Each actual batch still needs to be checked on its own.
Individualised products reuse some components and personalise others, and the two need separate evidence. In the phase 1 study of autogene cevumeran in resected pancreatic cancer (Rojas et al., 2023), individual vaccines of up to 20 neoantigens per patient were made in real time as uridine mRNA-lipoplex nanoparticles; 16 patients received atezolizumab and the vaccine, 15 subsequently received mFOLFIRINOX chemotherapy, and new neoantigen-specific T cells were detected in 8 of the 16 patients, and it shows one defined design carrying individual messages, not that all RNA vaccines share a recipe or outcome. In mice, a peptide-TLR-7/8a conjugate platform was built to self-assemble into nanoparticles of uniform size (about 20 nm) whatever the peptide, to address the physicochemical variability of neoantigens (Lynn et al., 2020). For autologous CAR T cells, FDA's 2024 guidance notes variability in the starting cells and recommends maintaining chain of identity from collection to administration, with at least two unique identifiers on labels of autologous products. A shared process and specification can support consistent handling and repeatable testing, but they do not establish that a new sequence or a changed process is equivalent to an earlier one, that a lot made for one recipient can be accepted on another recipient's results, or that the encoded targets are presented and recognised in a patient. 'Platform' here is a descriptive term for reuse, not a regulatory designation.
Shares CDMO (contract development and manufacturing organisation), Personalised neoantigen (mRNA) vaccines.
Shares CDMO (contract development and manufacturing organisation), mRNA and lipid nanoparticle manufacturing, Autologous CAR-T manufacturing, batch by batch.
Shares mRNA and lipid nanoparticle manufacturing, Personalised neoantigen (mRNA) vaccines.
Shares CDMO (contract development and manufacturing organisation), mRNA and lipid nanoparticle manufacturing, Personalised neoantigen (mRNA) vaccines.
Shares Batch release (lot disposition), Good manufacturing practice (GMP), Autologous CAR-T manufacturing, batch by batch.
Shares mRNA and lipid nanoparticle manufacturing, Personalised neoantigen (mRNA) vaccines.
Shares mRNA and lipid nanoparticle manufacturing, Personalised neoantigen (mRNA) vaccines.
Shares mRNA and lipid nanoparticle manufacturing, Autologous CAR-T manufacturing, batch by batch.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/